FindTrial
Sign In

Effects of dexmedetomidine as an adjuvant in paravertebral block on propofol target-controlled infusion in breast cancer surgery

Effects of dexmedetomidine as an adjuvant in ultrasound-guided paravertebral block on propofol target-controlled infusion in breast cancer surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800016614
Enrollment
Unknown
Registered
2018-06-12
Start date
2018-07-01
Completion date
Unknown
Last updated
2018-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

radical mastectomy

Interventions

Control group:0.5% ropivacaine 0.3ml/kg
Dex group:0.5% ropivacaine 0.3ml/kg within dexmedetomidine 1 ug/kg

Sponsors

The Second Affiliated Hospital of Nantong University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: ASA grade I-II female patients aged 18-65 years old, scheduled for radical mastectomy under propofol general anesthesia.

Exclusion criteria

Exclusion criteria: Patients undergoing bilateral radical or with a history of allergy to local anesthetics, severe cardiovascular disease, cerebrovascular disease, peripheral neuropathy, hepatic or renal disorders, psychiatric disease, severe respiratory disease, and BMI=28 kg/m2 will be excluded.

Design outcomes

Primary

MeasureTime frame
loss of consciousness;laryngeal mask insertion;dose of propofol during surgery;dose of remifentanyl during surgery;—

Secondary

MeasureTime frame
awaken time;extubation time;Steward score;postoperative nausea and vomiting;VAS score;—

Countries

China

Contacts

Public ContactSaishuai Yang

The Second Affiliated Hospital of Nantong University

635788147@qq.com+86 0513 85061315

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 17, 2026